The competitive nature of type II photosensitizers in the transfer of excitation energy for the generation of singlet oxygen (O) presents significant challenges in the design of type I photosensitizers to produce the superoxide anion radical (O). In this study, we present an efficient method for the direct transformation of type II photosensitizers into type I photosensitizers through the implementation of an artificial light-harvesting system (ALHSs) involving a two-step sequential energy transfer process. The designed supramolecular complex (DNPY-SBE-β-CD) not only has the ability to generate O as type II photosensitizers, but also demonstrates remarkable fluorescence properties in aqueous solution, which renders it an efficient energy donor for the development of type I photosensitizers ALHSs, thereby enabling the efficient generation of O. Meanwhile, to ascertain the capability and practicality of this method, two organic reactions were conducted, namely the photooxidation reaction of thioanisole and oxidative hydroxylation of arylboronic acids, both of which display a high level of efficiency and exhibit significant catalytic performance. This work provides an efficient method for turning type II photosensitizers into type I photosensitizers by a two-step sequential energy transfer procedure.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10829035 | PMC |
http://dx.doi.org/10.1039/d3sc05820d | DOI Listing |
Photodiagnosis Photodyn Ther
December 2024
Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China. Electronic address:
Although there has been significant progress in current comprehensive anticancer treatments centered on surgery, postoperative recurrence and tumor metastasis still significantly affect both prognosis and quality of life of the patient. Hence, the development of precisely targeted tumor therapies and exploration of immunotherapy represent ideal strategies for tumor treatment. Photodynamic therapy (PDT) is a localized and relatively safe treatment modality that not only induces multiple modes of tumor cell death but also mediates the secondary immunological responses against tumor resistance and metastasis.
View Article and Find Full Text PDFJ Funct Biomater
December 2024
Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Pushchino 142290, Russia.
X-ray-induced photodynamic therapy (X-PDT) represents a promising new method of cancer treatment. A novel type of nanoscintillator based on cerium fluoride (CeF) nanoparticles (NPs) modified with flavin mononucleotide (FMN) has been proposed. A method for synthesizing CeF-FMN NPs has been developed, enabling the production of colloidal, spherical NPs with an approximate diameter of 100 nm, low polydispersity, and a high fluorescence quantum yield of 0.
View Article and Find Full Text PDFAdv Mater
December 2024
School of Science and Engineering, Shenzhen Institute of Aggregate Science and Technology, The Chinese University of Hong Kong (CUHK-Shenzhen), Shenzhen, Guangdong, 518172, P. R. China.
The existence of residual small-size tumors after surgery is a major factor contributing to the high recurrence rate of glioblastoma (GBM). Conventional adjuvant therapeutics involving both chemotherapy and radiotherapy usually exhibit unsatisfactory efficacy and severe side effects. Recently, two-photon photodynamic therapy (TP-PDT), especially excited by the second near-infrared (NIR-II) light, offers an unprecedented opportunity to address this challenge, attributed to its combinational merits of PDT and TP excitation.
View Article and Find Full Text PDFAdv Sci (Weinh)
December 2024
Department of Chemistry, School of Science, Xihua University, Chengdu, 610039, China.
Type-I photosensitizers (PSs) are among the most potential candidates for photodynamic therapy (PDT), as their low dependence on oxygen endow them with many advantages for treating hypoxic tumor. However, most of the reported type-I PSs have a contingency of molecular design, because electron transfer (ET) reaction is more difficult to achieve than energy transfer (EET) process. Therefore, it is urgent to understand molecular design mechanisms for type-I PSs.
View Article and Find Full Text PDFSAGE Open Med Case Rep
December 2024
Division of Dermatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Dermatomyositis (DM) is an autoimmune idiopathic inflammatory myopathy with characteristic dermatologic manifestations. Myositis-specific autoantibodies (MSAs) delineate DM subtypes and their prognoses. Uncommonly, patients present with distinct clinical features of DM, including photosensitive dermatitis, heliotrope rash, Gottron's papules, and nailfold changes; however, their autoimmune serology is negative for expected MSAs.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!